HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 75.4%

Neg 0% Neu 0% Pos 75.4%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.